About this Course

Jointly provided by Postgraduate Institute for Medicine and Parkinson & Movement Disorder Alliance 

Release date: January 30, 2023

Expiration date: January 30, 2025

Estimated time to complete activity: 115 minutes

www.pimed.com

 Target Audience

This course is for movement disorder specialists, neurologists, advanced practice providers, and other healthcare professionals involved in the care of patients with a movement or related disorder.  

Educational Objectives

After completing this activity, the participant should be better able to:

  • Discuss the treatment options for management of Parkinson’s disease psychosis (PDP).
  • Appraise new research on safety, risks, along with efficacy of pimavanserin versus atypical antipsychotics in treatment of PDP
  • Identify patients to be treated for PDP and educate them on options for management
  • Apply best evidence-based guidelines into standard practice

Faculty

Kelly Papesh, DNP
Director, APProvider Initiatives
Parkinson & Movement Disorder Alliance

Aaron Ritter, MD
Director of the Memory & Cognitive Disorders Program and Center for Integrative Brain Health
Hoag's Pickup Family Neurosciences Institute

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Kelly Papesh, DNP – Speakers Bureau: Amneal, Acorda Therapeutics, AbbVie.

Aaron Ritter, MD - has nothing to disclose.

The PIM planners and others have nothing to disclose. 

The PMD Alliance planners and others have nothing to disclose.

All identified conflicts of interest are thoroughly vetted and mitigated according to PIM policy. 

Joint Accreditation Statement 

 Jointly%20Accredited%20Provider%20TMIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PMD Alliance.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of:

1.75 AMA PRA Category 1 Credit(s)™

1.75 AAPA Category 1 Credit(s)

1.75 AANC Contact Hour(s)

Learners should claim only the credit commensurate with the extent of their participation in the activity.

Computer System Requirements

A smartphone, tablet, or computer with access to the internet.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Commercial Support

This activity is supported by an independent medical education grant from Acadia Pharmaceuticals.

Method of Participation and Request for Credit

In order to obtain your CE certificate, please follow the steps below at the conclusion of the activity:

  1. Go to www.cmeuniversity.com
  2. Login or Create a New Account (will take less than 1 minute)
    • If you receive a message when creating a new account that “the email you entered is already in use”, please click the Forgot my Username or Password link to have your Username and Password sent to you via email
    • After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
  3. While logged in, go to https://www.cmeuniversity.com/course/take/123604
  4. Choose the type of credit you desire
  5. Complete the online Evaluation
  6. Receive an immediate CE Certificate to download and/or print for your files


If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com or PMD Alliance at education@pmdalliance.org

Instructors

Kelly Papesh, DNP

Advanced Practice Provider in Movement Disorders

Kelly Papesh, MSN, DNP is a board-certified family nurse practitioner specializing in movement disorders. After completing her Bachelor of Science in nursing at the University of Wisconsin-Oshkosh, she completed a Master of Science in nursing and a doctorate in Nursing Practice from Frontier Nursing University in Versailles, KY. She has extensive experience as a registered nurse in neurology and patient case management and over four years of experience specializing in movement disorders. Her clinical practice has focused on neurology assessment, diagnosis, treatment and management of patients with a variety of movement disorders including Parkinson disease, essential tremor and Huntington disease.

Aaron Ritter, MD

Larkin Family Endowed Chair in Integrative Brain Health

Aaron Ritter, M.D., is the Larkin Family Endowed Chair in Integrative Brain Health and Director of the Memory & Cognitive Disorders Program in Hoag’s Pickup Family Neurosciences Institute. Dr. Ritter previously practiced at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas where he led programs and research studies involving cognitive disorders and dementias. At the Cleveland Clinic he also served as principal investigator for the Center for Neurodegeneration and Translational Neurosciences, co-director of the Huntington Disease Comprehensive Care Clinic, and the Department Lead of Cognitive Disorders. He also led the Nevada Exploratory Alzheimer's Disease Research Center. He is interested in improving early diagnosis of neurodegenerative diseases such as Alzheimer's, Lewy body dementia, and chronic traumatic encephalopathy.

Course curriculum

    1. Educational Objectives

    2. Available CME/CNE Credit

    1. Pre Test

    1. Mortality Among Parkinson’s Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries

    1. Presentation: Psychosis in PD by Aaron Ritter, MD

    1. Patient Profile 1

    2. Reflection Question 1

    3. Treatment and Management Discussion 1

    4. Patient Profile 2

    5. Reflection Question 2

    6. Treatment and Management Discussion 2

    7. Patient Profile 3

    8. Reflection Question 3

    9. Treatment and Management Discussion 3

    10. Patient Profile 4

    11. Reflection Question 4

    12. Treatment and Management Discussion 4

    1. Post Test

About this course

  • Free
  • 18 lessons
  • 1.5 hours of video content